Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Chemotherapy in Gastric Cancer
NCT01787539Phase 3Unknown
- Sponsor
- Medical University of Lublin
- Start
- Feb 2013
- Primary completion
- Feb 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of epirubicin, oxaliplatin, capecitabine in gastric cancer (GC), sponsored by Medical University of Lublin. Status: unknown.
02
Drugs
epirubicinoxaliplatincapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01787539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01787539.